Prognosis for women with breast cancer not worse for those with family history

the ONA take:

A family history of breast cancer does not influence prognosis for women with breast cancer, according to results of a new large study from UK researchers. Approximately one-quarter of breast cancer cases in developed countries are thought to be hereditary.

The researchers conducted an analysis of the Prospective Outcomes in Sporadic versus Hereditary breast cancer (POSH) study, which included 2,850 women younger than 41 years with a breast cancer diagnosis and were treated in the United Kingdom.

POSH investigators had recorded information on patients’ tumors, treatment, family history of breast/ovarian cancer, and personal characteristics over a 15-year period.

In this study, no significant differences were found in cancer recurrence rates between women with a family history and those with no family history.

Future investigations will focus on the impact of certain gene variants on the effectiveness of different anticancer treatments.

Prognosis for women with breast cancer is not worse for those with a family history of the disease
A family history of breast cancer does not influence prognosis for women with breast cancer.
A new large study finds that women who are diagnosed with breast cancer and have a family history of the disease face no worse of a prognosis after treatment than other women with breast cancer.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs